164 related articles for article (PubMed ID: 36622366)
1. Dual inhibition of HSF1 and DYRK2 impedes cancer progression.
Tandon V; Moreno R; Allmeroth K; Quinn J; Wiley SE; Nicely LG; Denzel MS; Edwards J; de la Vega L; Banerjee S
Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36622366
[TBL] [Abstract][Full Text] [Related]
2. The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Moreno R; Banerjee S; Jackson AW; Quinn J; Baillie G; Dixon JE; Dinkova-Kostova AT; Edwards J; de la Vega L
Cell Death Differ; 2021 May; 28(5):1563-1578. PubMed ID: 33268814
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Banerjee S; Wei T; Wang J; Lee JJ; Gutierrez HL; Chapman O; Wiley SE; Mayfield JE; Tandon V; Juarez EF; Chavez L; Liang R; Sah RL; Costello C; Mesirov JP; de la Vega L; Cooper KL; Dixon JE; Xiao J; Lei X
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24881-24891. PubMed ID: 31754034
[TBL] [Abstract][Full Text] [Related]
4. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Banerjee S; Ji C; Mayfield JE; Goel A; Xiao J; Dixon JE; Guo X
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8155-8160. PubMed ID: 29987021
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of DYRK2 in cancer.
Tandon V; de la Vega L; Banerjee S
J Biol Chem; 2021; 296():100233. PubMed ID: 33376136
[TBL] [Abstract][Full Text] [Related]
6. mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis.
Chou SD; Prince T; Gong J; Calderwood SK
PLoS One; 2012; 7(6):e39679. PubMed ID: 22768106
[TBL] [Abstract][Full Text] [Related]
7. The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.
Santopolo S; Riccio A; Rossi A; Santoro MG
Cell Mol Life Sci; 2021 Feb; 78(3):1113-1129. PubMed ID: 32607595
[TBL] [Abstract][Full Text] [Related]
8. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes.
Rossi A; Riccio A; Coccia M; Trotta E; La Frazia S; Santoro MG
J Biol Chem; 2014 May; 289(18):12705-15. PubMed ID: 24619424
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.
Yang T; Ren C; Lu C; Qiao P; Han X; Wang L; Wang D; Lv S; Sun Y; Yu Z
Cancer Res; 2019 Oct; 79(20):5233-5244. PubMed ID: 31409638
[TBL] [Abstract][Full Text] [Related]
11. AKT1 mediates multiple phosphorylation events that functionally promote HSF1 activation.
Lu WC; Omari R; Ray H; Wang J; Williams I; Jacobs C; Hockaden N; Bochman ML; Carpenter RL
FEBS J; 2022 Jul; 289(13):3876-3893. PubMed ID: 35080342
[TBL] [Abstract][Full Text] [Related]
12. Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux.
Samarasinghe B; Wales CT; Taylor FR; Jacobs AT
Biochem Pharmacol; 2014 Feb; 87(3):445-55. PubMed ID: 24291777
[TBL] [Abstract][Full Text] [Related]
13. HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.
Fok JHL; Hedayat S; Zhang L; Aronson LI; Mirabella F; Pawlyn C; Bright MD; Wardell CP; Keats JJ; De Billy E; Rye CS; Chessum NEA; Jones K; Morgan GJ; Eccles SA; Workman P; Davies FE
Clin Cancer Res; 2018 May; 24(10):2395-2407. PubMed ID: 29391353
[No Abstract] [Full Text] [Related]
14. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
15. Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo.
Tandon V; Vala RM; Chen A; Sah RL; Patel HM; Pirrung MC; Banerjee S
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35088066
[TBL] [Abstract][Full Text] [Related]
16. Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Correa-Sáez A; Jiménez-Izquierdo R; Garrido-Rodríguez M; Morrugares R; Muñoz E; Calzado MA
Cell Mol Life Sci; 2020 Dec; 77(23):4747-4763. PubMed ID: 32462403
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
[TBL] [Abstract][Full Text] [Related]
18. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter.
Yoon YJ; Kim JA; Shin KD; Shin DS; Han YM; Lee YJ; Lee JS; Kwon BM; Han DC
J Biol Chem; 2011 Jan; 286(3):1737-47. PubMed ID: 21078672
[TBL] [Abstract][Full Text] [Related]
19. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract][Full Text] [Related]
20. The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters.
Kim JA; Kim Y; Kwon BM; Han DC
J Biol Chem; 2013 Oct; 288(40):28713-26. PubMed ID: 23983126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
